Status:
COMPLETED
DURABILITY-200: EverFlex 200mm Long Nitinol Stents in TASC C&D Femoropopliteal Lesions
Lead Sponsor:
Flanders Medical Research Program
Conditions:
Peripheral Vascular Disease
Intermittent Claudication
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The objective of this clinical investigation is to evaluate the long-term (up to 12 months) outcome of the 200 mm long self-expanding nitinol EverFlex (ev3) stent in long femoropopliteal lesions (TASC...
Eligibility Criteria
Inclusion
- GENERAL
- De novo, restenotic or reoccluded lesion located in the femoropopliteal arteries suitable for stenting
- Patient presenting a score from 2 to 5 following Rutherford classification
- Patient is willing to comply with specified follow-up evaluations at the specified times
- Patient is \>18 years old
- Patient (or their legal representative) understands the nature of the procedure and provides written informed consent, prior to enrolment in the study
- Prior to enrollment, the guidewire has crossed target lesion
- Patient is eligible for treatment with the self-expanding nitinol EverFlex (ev3) stent
- ANGIOGRAPHIC
- The target lesion is located within the native femoropopliteal artery until maximally 3 cm proximally of the knee joint.
- The target lesion has angiographic evidence of stenosis or restenosis \> 50% or occlusion which can be passed with standard guidewire manipulation
- The target lesion, visually estimated, has a minimal length of 15 cm and can be categorized as either a type C or D lesions according the TASC II guidelines
- Target vessel diameter visually estimated is \>4mm and \<6.5 mm
- There is angiographic evidence of at least one-vessel-runoff to the foot
Exclusion
- Presence of another stent in the target vessel that was placed during a previous procedure
- Presence of an aortic thrombosis or significant common femoral ipsilateral stenosis
- Previous by-pass surgery in the same limb
- Patients for whom antiplatelet therapy, anticoagulants or thrombolytic drugs are contraindicated
- Patients who exhibit persistent acute intraluminal thrombus of the proposed lesion site
- Perforation at the angioplasty site evidenced by extravasation of contrast medium
- Patients with known hypersensitivity to nickel-titanium
- Patients with uncorrected bleeding disorders
- Aneurysm located at the level of the SFA
- Female patient with child bearing potential not taking adequate contraceptives or currently breastfeeding
- Life expectancy of less than twelve months
- Ipsilateral iliac treatment before the target lesion procedure with a residual stenosis \> 30% or ipsilateral iliac treatment conducted after the target lesion procedure
- Use of thrombectomy, artherectomy or laser devices during procedure
- Any planned surgical intervention/procedure within 30 days of the study procedure
- Any patient considered to be hemodynamically unstable at onset of procedure
- Patient is currently participating in another investigational drug or device study that has not completed the entire follow up period.
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00637741
Start Date
March 1 2008
End Date
November 1 2010
Last Update
December 1 2010
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Imelda Hospital
Bonheiden, Belgium, 2820
2
AZ Sint-Blasius
Dendermonde, Belgium, 9200